RT Journal Article
SR Electronic
T1 Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP 209
OP 216
DO 10.1136/ijgc-00009577-200503000-00004
VO 15
IS 2
A1 H. T. See
A1 R. S. Freedman
A1 A. P. Kudelka
A1 T. W. Burke
A1 D. M. Gershenson
A1 S. Tangjitgamol
A1 J. J. Kavanagh
YR 2005
UL http://ijgc.bmj.com/content/15/2/209.abstract
AB The objective of the analysis was to determine the effectiveness of re-treating patients with ovarian cancer, primary peritoneal cancer, and fallopian tube cancer with carboplatin after being deemed platinum resistant. From a database period January 1, 1996, to December 12, 2002, 34 patients were identified who received nonplatinum agents before resuming treatment with carboplatin. The median age was 65 years, and a median of two nonplatinum chemotherapy (range 1–5) prior to re-treatment with carboplatin was received. The median platinum-free interval from the time platinum was last received to re-treatment with carboplatin was 15.2 months (95% confidence interval [CI] 12.6–17.9; range 6.2–47.0). A median number of four cycles of carboplatin (range 1–11) was received. Two patients (5.9%) achieved partial response, while 21 patients (61.7%) achieved stable disease. The median time to progression for these 23 patients after re-treatment with carboplatin was 5.7 months (95% CI 5.2–6.3; range 1.8–15.3). Twenty-seven patients have died, and all patients have progressed. Seven patients are still receiving salvage therapy. The median overall survival from the time deemed to be platinum resistant is 23.2 months (95% CI 20.1–26.4). Patients who have been deemed platinum resistant may still benefit from platinum re-treatment after an interval of treatment with nonplatinum agents